Hospital Variation in Treatment Patterns and Oncological Outcomes for Patients with Muscle-invasive and Metastatic Bladder Cancer in the Netherlands

Overview

Journal World J Urol

Specialty Urology

Date 2022 Apr 10

PMID 35397692

Authors

Daan J Reesink

Ewoudt M W van de Garde

Paul van der Nat

Diederik M Somford

Maartje Los

Simon Horenblas

Harm H E van Melick

Affiliations

Soon will be listed here.

Abstract

Purpose: Population-based studies on treatment patterns in oncology and corresponding clinical outcomes can help identify strategies towards optimal value for patients. This study was performed to describe the variation in treatment patterns and major oncological outcomes for muscle-invasive or metastatic bladder cancer (MIBC/mBC) patients in the Netherlands.

Methods: Patients diagnosed with cT2-4aN0-3M0-1 disease between 2008 and 2016 in seven large teaching hospitals in the Netherlands were included. Baseline characteristics, disease stage, intended and definitive treatment, and oncological outcomes were collected. Patients were categorized based on cTNM-stage: (1) cT2-4aN0M0, (2) cT2-4aN1-3M0 and (3) cT4b and/or M1.

Results: The total study population comprised 1853 patients, of which 1303 patients were diagnosed with cT2-4aN0M0 disease. Overall, curative treatment was intended in 81% (range 74-85%, P value = 0.132). Radical cystectomy (RC) and curative radiotherapy (RTx) ranged between hospitals from 42 to 66% and 13 to 27%, respectively (P value < 0.001). For 334 patients staged cT4b and/or M1, frequencies for palliative therapy and best supportive care (no anti-cancer therapy) ranged between hospitals from 20 to 54% and 44 to 71%, respectively (P value < 0.001). There was no association between hospital site and overall survival (OS) in a univariable and multivariable Cox regression for survival analysis (after adjusting for age and cT-stage), for all three cTNM-groups. Neoadjuvant or induction chemotherapy (NAIC) utilization rates before RC ranged from 8 to 38% (P value < 0.001).

Conclusions: There is large inter-hospital variation in treatment intent in MIBC/mBC patients. This variation does not seem to translate to differences in overall survival rates. There is an ongoing trend of increased use of RC. Utilisation of NAIC is relatively low considering European guideline recommendations.

References

van der Vlies E, Los M, Stijns P, van Hengel M, Blaauw N, Bos W . Preoperative frailty and outcome in patients undergoing radical cystectomy. BJU Int. 2020; 126(3):388-395. DOI: 10.1111/bju.15132. View

Schrag D, Mitra N, Xu F, Rabbani F, Bach P, Herr H . Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005; 65(6):1118-25. DOI: 10.1016/j.urology.2004.12.029. View

Grossman H, Natale R, Tangen C, Speights V, Vogelzang N, Trump D . Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349(9):859-66. DOI: 10.1056/NEJMoa022148. View

Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar M . International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29(16):2171-7. PMC: 3107740. DOI: 10.1200/JCO.2010.32.3139. View

Moschini M, Mattei A, Cornelius J, Shariat S, Delloglio P, Zaffuto E . Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World J Urol. 2018; 36(4):639-644. DOI: 10.1007/s00345-018-2190-1. View

Kim H, Pak S, Park K, Kim M, Kim J, Kim M . Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?. Clin Genitourin Cancer. 2019; 18(1):50-55. DOI: 10.1016/j.clgc.2019.09.018. View

Witjes J, Bruins H, Cathomas R, Comperat E, Cowan N, Gakis G . European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2020; 79(1):82-104. DOI: 10.1016/j.eururo.2020.03.055. View

von der Maase H, Sengelov L, Roberts J, Ricci S, Dogliotti L, Oliver T . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23(21):4602-8. DOI: 10.1200/JCO.2005.07.757. View

De Santis M, Bellmunt J, Mead G, Kerst J, Leahy M, Maroto P . Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2011; 30(2):191-9. PMC: 3255563. DOI: 10.1200/JCO.2011.37.3571. View

10.

Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W . A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011; 12(3):211-4. DOI: 10.1016/S1470-2045(10)70275-8. View

11.

Nogue-Aliguer M, Carles J, Arrivi A, Juan O, Alonso L, Font A . Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer. 2003; 97(9):2180-6. DOI: 10.1002/cncr.10990. View

12.

Goossens-Laan C, Visser O, Wouters M, Jansen-Landheer M, Coebergh J, van de Velde C . Variations in treatment policies and outcome for bladder cancer in the Netherlands. Eur J Surg Oncol. 2010; 36 Suppl 1:S100-7. DOI: 10.1016/j.ejso.2010.06.003. View

13.

Gray P, Fedewa S, Shipley W, Efstathiou J, Lin C, Zietman A . Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2012; 63(5):823-9. DOI: 10.1016/j.eururo.2012.11.015. View

14.

Jahnson S, Damm O, Hellsten S, Holmang S, Liedberg F, Ljungberg B . A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol. 2009; 43(4):271-6. DOI: 10.1080/00365590902909778. View

15.

John J, Varughese M, Cooper N, Wong K, Hounsome L, Treece S . Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England. Eur Urol Focus. 2020; 7(2):359-365. DOI: 10.1016/j.euf.2020.01.013. View

16.

Reesink D, van de Garde E, Somford D, Meijer R, Los M, Biesma D . Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative. Eur Urol Open Sci. 2021; 26:18-26. PMC: 8317903. DOI: 10.1016/j.euros.2021.01.014. View

17.

Fonteyne V, Ost P, Bellmunt J, Droz J, Mongiat-Artus P, Inman B . Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol. 2017; 73(1):40-50. DOI: 10.1016/j.eururo.2017.03.019. View

18.

Bos M, Marmolejo R, Rasch C, Pieters B . Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review. J Contemp Brachytherapy. 2014; 6(2):191-9. PMC: 4105649. DOI: 10.5114/jcb.2014.43777. View

19.

Bajaj A, Martin B, Bhasin R, Hentz C, Block A, Harkenrider M . The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2018; 100(4):851-857. DOI: 10.1016/j.ijrobp.2017.11.040. View

20.

Hermans T, Fransen van de Putte E, Horenblas S, Meijer R, Boormans J, Aben K . Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study. Eur J Cancer. 2016; 69:1-8. DOI: 10.1016/j.ejca.2016.09.015. View